Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (29288)	9/19/1999 11:06:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 32384

Cylexin abandoned, very poor results on phase III. Cytel was in charge of the drug, they gave up. Cylexin future is maybe zero for acute conditions, unless some chronic disease indication could be found or a new related compound, this is a close chapter. Ligand got some early license money (small amount) on it from Cytel It is one of the left over of the bioactive carbohydrates program from Glycosomething. This platform technology seems to be on Ligand basement, forgotten, probably some value on it since other companies are focus in this type of technology (look at how good is SAFS doing).